269 related articles for article (PubMed ID: 29659371)
21. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.
Geoerger B; Bergeron C; Gore L; Sender L; Dunkel IJ; Herzog C; Brochez L; Cruz O; Nysom K; Berghorn E; Simsek B; Shen J; Pappo A
Eur J Cancer; 2017 Nov; 86():358-363. PubMed ID: 29100190
[TBL] [Abstract][Full Text] [Related]
22. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
24. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
25. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
[TBL] [Abstract][Full Text] [Related]
26. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
Keilholz U; Mehnert JM; Bauer S; Bourgeois H; Patel MR; Gravenor D; Nemunaitis JJ; Taylor MH; Wyrwicz L; Lee KW; Kasturi V; Chin K; von Heydebreck A; Gulley JL
J Immunother Cancer; 2019 Jan; 7(1):12. PubMed ID: 30651126
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
[TBL] [Abstract][Full Text] [Related]
28. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study.
Urun Y; Yasar HA; Turna H; Esin E; Sedef AM; Alkan A; Oksuzoglu B; Ozdemir N; Sendur MN; Sezer A; Kılıckap S; Utkan G; Akman T; Akbulut H; Celik I; Abalı H
J Oncol Pharm Pract; 2019 Oct; 25(7):1658-1664. PubMed ID: 30400750
[TBL] [Abstract][Full Text] [Related]
30. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bastholt L; Mortier L; Thomas L; Tahir S; Hauschild A; Hassel JC; Hodi FS; Taitt C; de Pril V; de Schaetzen G; Suciu S; Testori A
N Engl J Med; 2016 Nov; 375(19):1845-1855. PubMed ID: 27717298
[TBL] [Abstract][Full Text] [Related]
31. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
[TBL] [Abstract][Full Text] [Related]
32. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman S; Heemskerk B; van Tinteren H; van den Brom RR; Hospers GA; van den Eertwegh AJ; Kapiteijn EW; de Groot JW; Soetekouw P; Jansen RL; Fiets E; Furness AJ; Renn A; Krzystanek M; Szallasi Z; Lorigan P; Gore ME; Schumacher TN; Haanen JB; Larkin JM; Blank CU
Cancer Immunol Immunother; 2014 May; 63(5):449-58. PubMed ID: 24609989
[TBL] [Abstract][Full Text] [Related]
33. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
34. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
35. Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings.
Cervantes J; Rosen A; Dehesa L; Dickinson G; Alonso-Llamazares J
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):43-49. PubMed ID: 30389125
[TBL] [Abstract][Full Text] [Related]
36. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Mangana J; Dimitriou F; Braun R; Ludwig S; Dummer R; Barysch MJ
Melanoma Res; 2019 Dec; 29(6):648-654. PubMed ID: 30870270
[TBL] [Abstract][Full Text] [Related]
37. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
[TBL] [Abstract][Full Text] [Related]
39. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
[TBL] [Abstract][Full Text] [Related]
40. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
